NCT04866303

Brief Summary

The COVID-19 pandemic has disproportionately affected American Indian (AI) and Latino communities, and these groups also have increased risk of poor prognosis due to high rates of chronic disease such as diabetes, cardiovascular disease, and cancer. In the northwestern United States, AI and Latino communities already face significant disparities in health care access, which have been further exacerbated by the COVID-19 pandemic. In the proposed study, Protecting Our Community: A Pragmatic Randomized Trial of Home-Based COVID Testing with Native American and Latino Communities, the investigators will leverage our long-term community-based participatory research partnerships to test the hypothesis that home-based testing will be feasible, impactful, and better-accepted using active delivery of test kits by trusted community health educators in two vulnerable, high-risk rural communities. Our two long-term partner communities are the Flathead Indian Reservation of the Confederated Salish and Kootenai Tribes in Montana, and the Yakima Valley of Washington, a large Latino community. The investigators will determine the cultural, social, behavioral, and economic barriers to home-based SARS-CoV-2 testing; culturally adapt and enhance home-testing educational materials and create home-testing instructional graphics and YouTube videos; conduct a 2-arm pragmatic randomized trial of active (delivered by community health educator) vs. passive (without community health educator) home-based testing kits (n = 200/community) for testing completion; and create a model for community-driven testing protocols that can have significant impact for increasing home-based testing uptake among AI and Latino communities nationally. This work will enable underserved AI and Latino communities to take full advantage of the coming wave of rapid point-of-care home tests and decrease the significant impact of COVID-19 in their communities.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
273

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Apr 2021

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 26, 2021

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

April 27, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 29, 2021

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 25, 2022

Completed
12 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 9, 2022

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

August 30, 2023

Completed
Last Updated

December 7, 2023

Status Verified

December 1, 2023

Enrollment Period

10 months

First QC Date

April 27, 2021

Results QC Date

February 23, 2023

Last Update Submit

December 5, 2023

Conditions

Keywords

SARS-CoV-2COVID-19home-based testingat home testing

Outcome Measures

Primary Outcomes (2)

  • SARS-CoV-2 Home-testing Kit Completion Active vs. Passive Arms

    Comparing the completed and successfully-completed test kits by study arm (randomization to either the active or passive arm)

    14 days from randomization for both completed and successfully-completed measurements

  • SARS-CoV-2 Home-testing Kit Successfully-Completed Active vs. Passive Arms

    SARS-CoV-2 Home-testing Kit successfully-completed by study arm (randomization to either the active or passive arm)

    14 days from randomization for both completed and successfully-completed measurements

Study Arms (2)

Active delivery

EXPERIMENTAL

For the participants randomized to the active arm will have their home collection kit registered on their behalf by bilingual (Spanish and English) community health workers, who are trusted community members. Home testing kits augmented with study developed materials will direct participants to contact the study team for assistance.

Diagnostic Test: Home-based SARS-CoV-2 test kit

Passive delivery

EXPERIMENTAL

Participants randomized to the passive arm will receive a home test kit augmented with instructions on how to self-register their kit online, and will be directed to contact Everlywell for assistance, if needed.

Diagnostic Test: Home-based SARS-CoV-2 test kit

Interventions

A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit assistance by community health educators vs. passive kit delivery. Will be done with two partner communities, Yakima Valley Latino community in WA and Flathead Reservation, American Indian community in MT. N = 200 participants in each community.

Active deliveryPassive delivery

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years old or older
  • Member of study community
  • No current significant symptoms consistent with COVID-19

You may not qualify if:

  • \< 18 years old
  • Not a member of the study community
  • Current significant symptoms consistent with COVID-19

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Salish Kootenai College

Pablo, Montana, 59855, United States

Location

Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Results Point of Contact

Title
Clinical Trial Manager
Organization
University of Washington

Study Officials

  • Alexandra K Adams, MD, PhD

    Montana State University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: A two-arm pragmatic randomized trial of SARS-CoV-2 home-based testing kit completion using active kit delivery by community health educators vs. passive kit delivery via mail.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 27, 2021

First Posted

April 29, 2021

Study Start

April 26, 2021

Primary Completion

February 25, 2022

Study Completion

March 9, 2022

Last Updated

December 7, 2023

Results First Posted

August 30, 2023

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

In conjunction with tribal partners on the Flathead Reservation and at Salish Kootenai College in Montana, and with community partners in the Yakima Valley in Washington, we have developed a Data Sharing Plan. We will work closely with the Coordination and Data Collection Center (CDCC); the Social, Ethical, and Behavioral Implications program (SEBI); and the RADx-Up Consortium throughout the study to implement the Plan. All data will be deidentified and assigned an anonymous code by a member of the study team in each community before sharing with the broader study team for analysis. In addition, data collection instruments (including surveys, focus group and key informant interview questions, informed consent forms, community data collection tools, and educational material), deidentified coded data, and analyzed study trial results will be shared with the CDCC, SEBI, and RADx-UP Consortium.

Locations